



Public Country-by-Country Report

Financial Year 2025

Report on corporate income tax or taxes of an identical or similar nature

Introduction

Alnylam Pharmaceuticals, Inc. and its group (“Alnylam” or the “Group”) publish this report on income tax information in accordance with Directive (EU) 2021/2101 (the public country-by-country reporting Directive), as transposed into the laws of the relevant Member States.

Alnylam is headquartered in the United States, and its ultimate parent undertaking is not governed by the law of a Member State. This report is therefore published, on behalf of the Group, by Alnylam Pharmaceuticals (Spain), S.L. – a medium-sized / large subsidiary undertaking established in Spain – and is filed and made publicly available in accordance with Additional Provision 11 of Law 22/2015 of 20 July on Statutory Audits, as amended by Law 28/2022. The report is made available on the company’s website and filed with the Commercial Register together with the documents forming part of the annual accounts within six months of the financial year-end.

The information presented covers all undertakings consolidated in the financial statements of the ultimate parent for the financial year ended 31 December 2025. Each EU Member State in which the Group operates is shown separately; each jurisdiction on Annex I of the EU list of non-cooperative jurisdictions, and each jurisdiction listed on Annex II for more than twelve months, is shown separately where the Group has a presence; all remaining jurisdictions are aggregated. All monetary amounts are expressed in US dollars (USD).

Section 1 General information

Name of ultimate parent of group / of standalone company	Alnylam Pharmaceuticals, Inc.
Country of registered office of ultimate parent undertaking	United States (US)
Date of start of financial year	01-01-2025
Date of end of financial year	31-12-2025
Reporting currency	USD
Application of option to report in accordance with taxation reporting instructions (Section III, Parts B and C, Annex III to Directive 2011/16/EU)	No
Name and registered office of the subsidiary undertaking which has published the report on behalf of an undertaking not governed by the law of a Member State	Alnylam Pharmaceuticals (Spain), S.L. – Paseo de la Castellana, núm. 95, Torre Europa, planta 23, 28046 Madrid
Name and address of a single branch which has published the report on behalf of an undertaking not governed by the law of a Member State	Not applicable
Language of report	English

Section 2 Overview of information on a country-by-country basis

Monetary amounts are expressed in US dollars (USD). Figures in parentheses are negative. Amounts are rounded to the nearest dollar; totals may not add up exactly.

Name of Member State or tax jurisdiction	Country code	No. of employees	Revenues	Profit/(loss) before tax	Income tax accrued (current year)	Income tax paid (cash basis)	Accumulated earnings
Austria	AT	3	10,782,664	343,293	68,856	46,466	864,258
Belgium	BE	3	2,717,907	131,380	33,160	45,198	588,877
Czechia	CZ	0	0	(30,895)	0	0	72,377
France	FR	38	100,393,160	5,409,342	1,408,762	660,354	7,999,325
Germany	DE	48	118,993,356	3,233,739	986,041	1,212,475	9,085,034
Italy	IT	28	116,152,714	2,992,386	1,143,444	2,792,657	4,625,866
Netherlands	NL	55	554,231,799	4,314,669	1,037,491	545,253	9,353,504
Portugal	PT	9	56,376,717	1,723,226	614,219	(170,700)	2,137,681
Spain	ES	31	47,263,805	1,234,622	431,739	318,756	3,464,563
Sweden	SE	8	8,689,714	180,541	57,135	149,173	1,109,645
All other tax jurisdictions (aggregated)	-	2,167	3,776,270,233	(53,328,347)	5,706,546	9,651,415	(8,773,855,887)
Total		2,390	4,791,872,070	(33,796,044)	11,487,393	15,251,046	(8,734,554,756)

The figures are aggregated from the individual financial statements of the Group's undertakings and translated into USD. This information may differ from the corresponding or similar items presented in the Group's consolidated financial statements, which are prepared under their own applicable accounting framework and, in particular, eliminate intra-group transactions that are not eliminated here.

The Germany and UK financial statements have not yet been approved; therefore, the related figures remain draft.

"All other tax jurisdictions (aggregated)" includes the Group's undertakings in the United States, the United Kingdom, Switzerland, Bermuda, Canada, Japan, Taiwan, Australia, Brazil and Argentina.

Section 3 List of subsidiaries and activities

The undertakings below are those consolidated in the financial statements of the ultimate parent that are established in an EU Member State or in a jurisdiction listed on Annex I or Annex II for more than twelve months. For each Member State, the brief description of the nature of activities reflects the actual activities of the undertaking(s) concerned.

Member State / tax jurisdiction	Country code	Name of subsidiary undertakings consolidated in the financial statements of the ultimate parent	Brief description of the nature of activities
Austria	AT	Alnylam Austria GmbH	Wholesale of pharmaceutical goods
Belgium	BE	Alnylam Belgium BVBA	Business and other management consultancy activities
Czechia	CZ	Alnylam Czech Rep s.r.o. (deregistered 21 March 2025)	Wholesale of pharmaceutical goods
France	FR	Alnylam France SAS	Wholesale of pharmaceutical goods
Germany	DE	Alnylam Germany GmbH Alnylam Europe AG (dormant)	Wholesale of pharmaceutical goods
Italy	IT	Alnylam Italy S.r.l.	Wholesale of pharmaceutical goods
Netherlands	NL	Alnylam Netherlands B.V.	Wholesale of pharmaceutical goods
Portugal	PT	ALNYPT Unipessoal LDA	Wholesale of pharmaceutical goods
Spain	ES	Alnylam Pharmaceuticals (Spain), S.L.	Wholesale of pharmaceutical goods
Sweden	SE	Alnylam Sweden AB	Wholesale of pharmaceutical goods

Section 4 Omitted information

Information omitted	Information omitted for other tax jurisdictions	Explanation of reason for omission
No information has been temporarily omitted from this report.	Not applicable	Not applicable

Disclosure of information omitted for previous financial years: not applicable (FY2025 is the first reporting period).

Section 5 Explanations for material discrepancies between income tax paid and accrued

Explanation of any material discrepancies between income tax paid and income tax accrued

Income tax paid on a cash basis represents tax actually settled during the financial year, whereas income tax accrued (current year) represents the current tax expense recognised for the financial year. Differences between the two amounts arise principally from timing: cash settlements in a given year include payments and refunds relating to prior financial years, advance and instalment payments, and the settlement of assessments, which do not necessarily coincide with the current-year accrual.